Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
 - EconoTimes)
NEW ORLEANS, Jan. 24, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 27, 2017 to file lead plaintiff applications in a securities class action lawsuit against Mallinckrodt Public Limited Company (NYSE:MNK), if they purchased the Company’s securities between November 25, 2014 and January 18, 2017, inclusive (the “Class Period”). The action is pending in United States District Court for the District of Columbia.
What You May Do
If you purchased securities of Mallinckrodt and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 27, 2017.
About the Lawsuit
The complaint alleges that, throughout the Class Period, Mallinckrodt and its CEO, Mark Trudeau, made a series of false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of Mallinckrodt’s revenues for HP Acthar Gel (“Acthar”), the only FDA-approved adrenocorticotropic hormone preparation. The action alleges that Acthar’s monopoly status was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
